



Chappaqua, NY (July 5, 2018) - A2A Pharmaceuticals Inc. (A2A), a biotechnology company committed to the advancement of innovative scientific research and new therapeutic agents, today announced 2nd Quarter 2018 results.

Highlights


A2A is delighted that Dr. Chaemin Lim has joined A2A as Chief Scientific Officer and Dr. Elena Diez-Cecilia has joined as Head of Business Development. Yuemin Bian also joined A2A as Head of Computational Chemistry. All three, have published important new discoveries in their research and are important additions to A2A's research and development.

Dr. Lim has a PhD in Medicinal Chemistry from Seoul National University and did postdoctoral research at the University of Pittsburgh. She has extensive experience in drug discovery and in advancing projects from early development stages to preclinical trials covering multiple therapeutic areas. She will be responsible for advancing A2A's growing pipeline of new drug candidates toward clinical trials.

Dr. Diez-Cecilia earned a Ph.D. in Medicinal Chemistry from Trinity College Dublin (Ireland) and a postdoctoral research fellowship from University of Toronto (Canada). She has over 8 years of experience in the USA, Canada and Europe Life Science markets. She has been involved with A2A since its inception and assumed the role of Director of Business Development in January 2018. She will be responsible for building partnerships with other pharmaceutical companies and innovation organizations to accelerate advancement towards FDA approval.

Yuemin Bian has a Masters degree from the University of Pittsburgh and is working with Chaemin on the design of novel candidates across A2A's pipeline while integrating new machine learning and artificial intelligence (AI) tools into the SCULPT platform.

Pipeline



- The leukemia program continues to advance with compelling data toward clinical trials for which our goal is IND-filing in 2019.
- The drug resistant bacterial Infection program is advancing with positive *in-vitro* results for very difficult to treat gram-negative infections. As with all of A2A's programs, the scaffolds are unique.
- Synthesis of new drug candidates for a large variety of cancers including pancreatic and lung cancer has been successfully carried out. Biological *in-vitro* testing and protein-protein YAP-TEAD binding affinity studies of the synthesized molecules will begin in August 2018.
- A2A has added 4 new programs to the pipeline. We are currently designing and will be testing new drug candidates for type 2 diabetes and Duchenne muscular dystrophy (DMD). In addition, 2 new oncology targets have been added, STING & Rad51.



The uniqueness of A2A's SCULPT platform radically accelerates lead drug discovery and optimization through systematic design, creating a broad range of highly selective new drug candidates for difficult to drug targets, including protein-protein interactions. This has resulted in A2A being able to attract numerous partnerships.

- As a result of winning the Artificial Intelligence Quickfire Challenge, A2A is moving into Johnson & Johnson's new JLABS @NYC facility in August 2018.
- Two new partnerships were formed in the 2nd quarter of 2018. 1) A cost and expertise sharing joint venture with InSilico Medicine to advance a new drug candidate for Duchenne muscular dystrophy (DMD) toward clinical trials. 2) A collaboration with a major university to advance a new drug candidate for cancer treatment.
- Work with Biomea Healthcare on the leukemia and drug resistant bacterial Infection programs continues to progress extremely well as do confidential collaborations with P&G on a cardiovascular indication and Novartis on a new cancer therapy.

After completion of over \$3 million financing with CPS Capital Group Pty Ltd, earlier this year, A2A ended the 2nd quarter of 2018 with \$3 million in cash. A2A's partnership centric early discovery business model is allowing A2A to advance a broad pipeline of new drug candidates with current financing predicted to last into 2020. However, in order to further accelerate growth, we will raise additional funds from strategic investors over the next 6-12 months.

We welcome the opportunity to discuss our progress and exciting developments with investors interested in our mission at any moment.

About A2A Pharmaceuticals, Inc.

A2A Pharmaceuticals Inc. is committed to the development of new therapeutic agents that serve highly unmet patient needs. Our focus areas are oncology and drug-resistant bacterial infections with programs recently initiated in muscular dystrophy and type 2 diabetes. Dr. Sotirios Stergiopolous, Chief Medical Officer of Ipsen, is the Chairman of the Board of Directors and Edward Painter is the Chief Executive Officer.

A2A's technology applies a proprietary therapeutic design methodology called SCULPT™, towards inhibiting difficult to drug targets including protein-protein interactions and other



A2A Pharmaceuticals Q2 2018 Update

enzymes of pharmacological importance in a range of diseases. SCULPT™ enables the design of novel ligands specifically to match the unique topological features of disease targets.

Targets for A2A antibiotic programs were selected based on their broad-spectrum applicability to gram-negative bacterial species, as well as novelty to circumvent rapid target-associated resistance. A unique bioinformatics approach was incorporated into the SCULPT process to yield candidates with "antibiotic-like" properties, in order to maximize the chances of activity and minimize drug efflux.

Edward Painter

Edward@atoms2applications.com

1 914 841 8818

A2APharma.com